Medartis Holding (MED) Stock Overview
A medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MED from our risk checks.
MED Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Medartis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 81.40 |
| 52 Week High | CHF 95.00 |
| 52 Week Low | CHF 51.00 |
| Beta | 1.27 |
| 1 Month Change | 3.30% |
| 3 Month Change | -7.18% |
| 1 Year Change | 44.58% |
| 3 Year Change | -9.15% |
| 5 Year Change | 74.30% |
| Change since IPO | 31.38% |
Recent News & Updates
Estimating The Intrinsic Value Of Medartis Holding AG (VTX:MED)
Nov 06
Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet
Sep 25Earnings Update: Medartis Holding AG (VTX:MED) Just Reported And Analysts Are Trimming Their Forecasts
Aug 22Investors Continue Waiting On Sidelines For Medartis Holding AG (VTX:MED)
Aug 21Recent updates
Estimating The Intrinsic Value Of Medartis Holding AG (VTX:MED)
Nov 06Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet
Sep 25Earnings Update: Medartis Holding AG (VTX:MED) Just Reported And Analysts Are Trimming Their Forecasts
Aug 22Investors Continue Waiting On Sidelines For Medartis Holding AG (VTX:MED)
Aug 21Returns At Medartis Holding (VTX:MED) Appear To Be Weighed Down
Apr 13We Think Medartis Holding's (VTX:MED) Robust Earnings Are Conservative
Mar 26
New CEO And Keri Touch Launch Will Accelerate US And LATAM Expansion
The strategic initiatives under new leadership in the U.S. and LATAM, including product launches and acquisitions, aim to improve revenue and market share.These 4 Measures Indicate That Medartis Holding (VTX:MED) Is Using Debt Reasonably Well
Mar 21Even With A 29% Surge, Cautious Investors Are Not Rewarding Medartis Holding AG's (VTX:MED) Performance Completely
Jan 20A Piece Of The Puzzle Missing From Medartis Holding AG's (VTX:MED) Share Price
Nov 27Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet
Nov 09The Strong Earnings Posted By Medartis Holding (VTX:MED) Are A Good Indication Of The Strength Of The Business
Aug 27Medartis Holding AG (VTX:MED) Doing What It Can To Lift Shares
Aug 21When Should You Buy Medartis Holding AG (VTX:MED)?
May 10Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation
Apr 11The Returns On Capital At Medartis Holding (VTX:MED) Don't Inspire Confidence
Feb 14Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around
Oct 24Is Medartis Holding (VTX:MED) A Risky Investment?
Oct 03Is Medartis Holding AG (VTX:MED) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 06Market Still Lacking Some Conviction On Medartis Holding AG (VTX:MED)
Jun 21Medartis Holding (VTX:MED) May Have Issues Allocating Its Capital
Jan 31Why Medartis Holding AG (VTX:MED) Could Be Worth Watching
Oct 30These Analysts Think Medartis Holding AG's (VTX:MED) Sales Are Under Threat
Sep 07When Should You Buy Medartis Holding AG (VTX:MED)?
Jul 29Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital
May 06At CHF123, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?
Feb 08Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around
Jan 18We Think Medartis Holding (VTX:MED) Can Stay On Top Of Its Debt
Nov 10Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital
Sep 29Some Investors May Be Worried About Medartis Holding's (VTX:MED) Returns On Capital
Jun 08How Much Of Medartis Holding AG (VTX:MED) Do Insiders Own?
Mar 16We're Watching These Trends At Medartis Holding (VTX:MED)
Feb 09
Medartis Holding (VTX:MED) Shareholders Have Enjoyed A 10% Share Price Gain
Jan 04What Type Of Shareholders Own The Most Number of Medartis Holding AG (VTX:MED) Shares?
Nov 19Shareholder Returns
| MED | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 6.7% | 4.1% | 2.4% |
| 1Y | 44.6% | -17.8% | 8.0% |
Return vs Industry: MED exceeded the Swiss Medical Equipment industry which returned -17.8% over the past year.
Return vs Market: MED exceeded the Swiss Market which returned 8% over the past year.
Price Volatility
| MED volatility | |
|---|---|
| MED Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: MED has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: MED's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,158 | Matthias Schupp | www.medartis.com |
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company’s medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides osteosynthesis products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names.
Medartis Holding AG Fundamentals Summary
| MED fundamental statistics | |
|---|---|
| Market cap | CHF 986.03m |
| Earnings (TTM) | -CHF 487.00k |
| Revenue (TTM) | CHF 236.34m |
Is MED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MED income statement (TTM) | |
|---|---|
| Revenue | CHF 236.34m |
| Cost of Revenue | CHF 49.38m |
| Gross Profit | CHF 186.96m |
| Other Expenses | CHF 187.45m |
| Earnings | -CHF 487.00k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 17, 2026
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 79.11% |
| Net Profit Margin | -0.21% |
| Debt/Equity Ratio | 44.3% |
How did MED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 19:10 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medartis Holding AG is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Burgansky | Research Partners AG |
| null null | Research Partners AG |
| Dylan van Haaften | Stifel, Equities Research |